Post-Amivantamab Supportive Medications and Subsequent Therapy
After completing amivantamab treatment, patients should receive platinum-based chemotherapy following standard non-driver alteration guidelines, with specific attention to prophylactic anticoagulation and dermatologic management during any ongoing therapy. 1, 2
Post-Infusion Supportive Medications
Premedication Requirements
Amivantamab requires specific premedications to mitigate infusion-related reactions (IRRs), which occur in approximately 67% of patients with IV administration 3, 4:
- Dexamethasone 8 mg orally twice daily starting 2 days before first infusion (C1D-2, C1D-1, and morning of C1D1) - this reduces IRR rates from 67% to approximately 22.5% 4
- Antipyretic (e.g., acetaminophen)
- Antihistamine (e.g., diphenhydramine) 5, 3
Important: The enhanced dexamethasone regimen (8 mg twice daily for 5 doses) is significantly more effective than standard 4 mg dosing and should be implemented routinely 4.
Prophylactic Anticoagulation
- Mandatory prophylactic anticoagulation is required when amivantamab is combined with lazertinib due to venous thromboembolism (VTE) risk of 9-14% 6
- Continue throughout treatment duration 1, 7
Dermatologic Prophylaxis
Given the EGFR-targeting mechanism, implement early dermatologic management 8:
- Topical corticosteroids for rash prevention
- Emollients for skin barrier protection
- Doxycycline 100 mg twice daily prophylactically for acneiform rash
- Nail care protocols for paronychia prevention (avoid tight footwear, keep nails short)
Subsequent Therapy After Amivantamab Completion
For EGFR Exon 19 Deletion or L858R Mutations (Post-Osimertinib Progression)
If amivantamab was given as second-line with chemotherapy 1, 2:
- Proceed to platinum-based chemotherapy following non-driver alteration guidelines
- Anti-PD-(L)1 agents with chemotherapy are NOT recommended (no survival benefit demonstrated in CheckMate 722 and KEYNOTE-789) 1
- Consider bevacizumab plus chemotherapy for adenocarcinoma histology if appropriate 1
If amivantamab was given first-line with lazertinib 7:
- Upon progression, offer platinum-based chemotherapy with or without amivantamab (if not previously received in combination)
- Repeat molecular profiling for emergent targetable alterations (T790M, MET amplification) 9
For EGFR Exon 20 Insertion Mutations
If amivantamab was first-line with chemotherapy 10:
- Subsequent therapy options per NSCL-K 4 of 5 guidelines (standard chemotherapy regimens)
- No specific targeted options currently available after amivantamab failure
If amivantamab was second-line monotherapy 10:
- Standard chemotherapy regimens
- Clinical trial enrollment strongly encouraged
Ongoing Adverse Event Management
Key Toxicities Requiring Continued Monitoring 8, 11:
Cutaneous reactions (most common):
- Rash: Topical corticosteroids, escalate to oral doxycycline or systemic corticosteroids
- Paronychia: Topical antibiotics, silver nitrate for granulation tissue
- Pruritus: Antihistamines, emollients
MET-related effects:
- Peripheral edema: Diuretics, compression stockings
- Hypoalbuminemia: Monitor albumin levels, nutritional support
Hematologic toxicity (when combined with chemotherapy):
- More pronounced with quadruplet regimens (amivantamab + lazertinib + chemotherapy)
- Standard growth factor support as needed 1
Critical Considerations
Switching Between IV and SC Formulations
- SC amivantamab demonstrates noninferior pharmacokinetics with reduced IRR rates (13% vs 66%) and shorter administration time 6
- Can switch between formulations based on patient preference and tolerability
- Maintain same premedication protocols
Radiation Therapy Compatibility
- Concurrent radiation with amivantamab is safe and feasible 11, 12
- No additional toxicities observed when given sequentially or concurrently
- Symptom relief achieved in 87% of palliative irradiations 12
When NOT to Continue Amivantamab
- Grade 4 IRRs: permanently discontinue 5, 3
- Severe interstitial lung disease/pneumonitis
- Uncontrolled VTE despite anticoagulation
- Disease progression with no clinical benefit
Common Pitfall: Do not add anti-PD-(L)1 therapy to chemotherapy after EGFR TKI progression—multiple phase III trials (CheckMate 722, KEYNOTE-789) showed no benefit and this approach is explicitly not recommended 1, 7.